SPARC2025-10-012025-12-31SPARC2025-04-012025-12-31SPARC2025-10-012025-12-31in-capmkt:OtherExpenses1MemberSPARC2025-10-012025-12-31in-capmkt:OtherExpenses2MemberSPARC2025-10-012025-12-31in-capmkt:OtherExpenses3MemberSPARC2025-04-012025-12-31in-capmkt:OtherExpenses1MemberSPARC2025-04-012025-12-31in-capmkt:OtherExpenses2MemberSPARC2025-04-012025-12-31in-capmkt:OtherExpenses3MemberSPARC2025-10-012025-12-31ItemsThatWillNotBeReclassifiedToProfitAndLoss1SPARC2025-10-012025-12-31ItemsThatWillNotBeReclassifiedToProfitAndLoss2SPARC2025-04-012025-12-31ItemsThatWillNotBeReclassifiedToProfitAndLoss1SPARC2025-04-012025-12-31ItemsThatWillNotBeReclassifiedToProfitAndLoss2SPARC2025-10-012025-12-31AuditorDomain1iso4217:INRiso4217:INRxbrli:shares532872SPARCNAINE232I01014Sun Pharma Advanced Research Company LimitedMain BoardEquity2025-04-012026-03-312026-02-092026-02-03INRLakhsQuarterlyThird quarterSingle segmentPharmaceutical Research and Development2026-02-0911:15:002026-02-0913:15:00Declaration of unmodified opinion2025-10-012025-12-31UnauditedConsolidated8450000008450000072100000003118000008780000025700000267000000764400000-679900000-123600000-80350000007000007000000-8042000000000-80420000011900000-792300000-79230000003245000001-2.48-2.4800-2.48-2.481 These unaudited consolidated financial results relate to Sun Pharma Advanced Research Company Limited (the 'Company') and its Wholly Owned Subsidiaries (together the ‘Group’) and are prepared by applying Ind AS 110 - "Consolidated Financial Statements". <BR> <BR> 2 The above unaudited consolidated financial results of the Company have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on February 09 2026. <BR> <BR> 3 The above unaudited consolidated financial results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules 2015 (Ind AS) as amended prescribed under Section 133 of the Companies Act 2013 read with relevant rules issued thereunder. <BR> <BR> 4 The Group has incurred cash losses in past quarters and in the current quarter. The Group has a support letter from its promoter group entity basis which its status as "Going Concern" continues. <BR> <BR> 5 The Government of India has consolidated 29 existing labour legislations into a unified framework comprising four labour codes as follows: Code on Wages 2019 Code on Social Security 2020 Industrial Relations Code 2020 and Occupational Safety Health and Working Conditions Code 2020 (collectively referred to as the "New Labour Codes"). The New Labour Codes are effective from November 21 2025 and introduce changes that include among other things setting a uniform definition of wages. The Government is in the process of issuing related rules. The New Labour Codes have implications on employee benefits including gratuity leave encashment and other related obligations. <BR> <BR> 6 On February 03, 2026, the United States Food and Drug Administrator granted a Rare Pediatric Disease Priority Review Voucher (PRV) associated with the approval of Sezaby®. The PRV is a tradeable voucher that can be redeemed to receive a priority review for a subsequent, separate drug application. <BR> <BR> 7 The Group has only one reportable business segment namely 'Pharmaceutical Research and Development'.2025-04-012025-12-31UnauditedConsolidated2595000009150000035100000018440000000920100000224900000781000008994000002306900000-1955900000-123600000-20795000000190000019000000-20814000000000-208140000012200000-2069200000-206920000003245000001-6.41-6.4100-6.41-6.41Clinical trial expenses / products development expense62700000Professional charges112800000Other expenses91500000Clinical trial expenses / products development expense198200000Professional charges401800000Other expenses299400000Items that will not be reclassified to profit or loss (net actuarial gain / (loss) on employee defined benefit plan)11300000Items that may be reclassified to profit or loss (exchange differences in translating the financial statements of subsidiary)60000011900000Items that will not be reclassified to profit or loss (net actuarial gain / (loss) on employee defined benefit plan)10000000Items that may be reclassified to profit or loss (exchange differences in translating the financial statements of subsidiary)22000001220000000001190000012200000UnauditedtrueSRBC AND CO LLPtrue2026-02-28